Due to a delay in the clinical timelines in Work Package 4 (primarily stemming from the longer study recruitment and analyses time for the first study, OC5-DB-01), the ELIMOX consortium requested an extension to the project timelines (Amendment 1).

This was discussed at depth with the REA. Following submission of an official request and updated documentation in July 2015, approval was given in August 2015 to extend ELIMOX by 12 months. This was primarily to extend the timelines for the clinical work package WP4.

Timelines for the management work package (WP1) and the exploitation and dissemination work package (WP5) were also extended from 24 to 36 months. Timelines for WP2 and WP3 remained as in the original application (i.e. ended at Month 24).